zalcitabine


Also found in: Dictionary, Thesaurus, Wikipedia.

zalcitabine

 [zal-si´tah-bēn]
a nucleoside analogueantiretroviral agent that inhibits the action of reverse transcriptase; used in the treatment of human immunodeficiency virus (HIV) infection, administered orally.

zalcitabine

/zal·ci·ta·bine/ (zal-si´tah-bēn) 2′3′-dideoxycytidine, an antiretroviral agent that inhibits the action of reverse transcriptase; used in the treatment of HIV infection.

zalcitabine

(zăl′sĭ-tə-bīn′)
n.
A nucleoside analog antiviral drug that inhibits the replication of retroviruses such as HIV by interfering with the enzyme reverse transcriptase. Also called ddC.

zalcitabine

an antiretroviral nucleoside reverse transcriptase inhibitor analog. Also called ddC, dideoxycytidine.
indications It was prescribed in combination with other drugs for the treatment of human immunodeficiency virus infections. The sale and distribution of this medication was discontinued in the United States in 2006.
contraindications The drug should not be given to patients with an allergy to zalcitabine or any of its components. Zalcitabine is not a cure, and acquired immunodeficiency syndrome patients may continue to acquire symptoms associated with the disease. Caution is recommended in patients with low CD4 cell counts, esophageal ulcers, numbness or tingling in the extremities, or a history of pancreatitis or alcohol abuse.
adverse effects The side effects most often reported include nausea, appetite loss, stomach pain, headache, dizziness, fatigue, dry mouth, and night sweats.

zalcitabine

ddC, Hivid AIDS A purine analogue that inhibits HIV reverse transcriptase; it is similar didanosine vis-á-vis survival, progression, CD4 count, adverse effects, efficacy. See Didanosine, Reverse transcriptase inhibitor. Cf Protease inhibitor.

zalcitabine

A REVERSE TRANSCRIPTASE inhibitor drug used in combination with other drugs to treat AIDS. A brand name is Hivid.

zalcitabine, (zal´sitə-bēn´),

n brand name: Hivid;
drug class: synthetic pyrimidine antiviral;
action: converted by cellular enzymes to active drug; functions as antimetabolite to inhibit replication of HIV in vitro;
uses: used in combination with zidovudine in advanced HIV infection, second-line monotherapy if AZT tolerant.
References in periodicals archive ?
5] Nonstandard abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; mtDNA, mitochondrial DNA; PBMC, peripheral blood mononuclear cell; nDNA, nuclear DNA; NASBA, nucleic acid sequence-based amplification; AZT, zidovudine; 3TC, lamivudine; IDV, indinavir; d4T stavudine; ddI, didanosine; ACTG, AIDS Clinical Trial Group; FCS, fetal calf serum; DMSO dimethyl sulfoxide; and ddC, zalcitabine.
Arons, we classified combination drug therapy used in the Florida Medicaid program into two groups: (i) two nucleoside analog drugs, including zidovudine (azt), didanosine (ddi), zalcitabine (ddc), stavudine (d4t), and lamivudine (3tc); (ii) one protease inhibitor and a pair of nucleoside analogs.
The other class of antiretroviral agents available in the United States--nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, and the new drug abacavir [2]--are not metabolized by CYP450.
The patient's medications on admission included zalcitabine, lamivudine, saquinavir, trimethoprim/ sulfamethoxazole, clindamycin, ciprofloxacin, ganciclovir, senna, naproxen, beclomethasone dipropionate, oxymetazoline HCl, morphine, potassium chloride, warfarin, and zolpidem.
Generic Name Recommended Dosage Didanosine (ddi) If >60 kg: 200 mg bid If <60 kg: 125 mg bid Lamivudine (3TC) If <50 kg: 2 mg/kg bid If >50 kg: 150 mg bid Stavudine (d4T) If >60 kg: 40 mg bid If <60 kg: 30 mg bid Zalcitabine (ddC) 0.
Zalcitabine (ddC, Dideoxycytidine, HIVID), Hoffmann-La Roche
Antiretroviral utilization was defined as self-reported use of zidovudine, didanosine, or zalcitabine.
Treatment of Human Inmmunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine.
Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-infected Patients with the Acquired Immunodeficiency Syndrome or Fewer than 200 CD4 Cells Per Cubic Millimeter, 335 New Eng.
The drug has been found to extend lives when combined with an older AIDS drug, zalcitabine (formerly called ddC).
However, since tests of zalcitabine are still in progress, the FDA approved the drug's use only in combination with the AIDS drug zidovudine, or AZT.
Additive to synergistic antiretroviral activity was observed when human T-lymphoid cells infected with the H9IIIB variant of HIV-1 were incubated with raltegravir in combination with non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, or nevirapine); nucleoside analog reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, tenofovir, zalcitabine, or zidovudine); protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir); or the entry inhibitor enfuvirtide.